Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection
Hariyanto et al.,
Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection,
Obesity Medicine, doi:10.1016/j.obmed.2020.100290 (meta analysis)
Meta analysis of 5 studies showing lower mortality with metformin use.
Currently there are
61 metformin studies and meta analysis shows:
Hariyanto et al., 18 Aug 2020, peer-reviewed, 2 authors.
Abstract: Obesity Medicine 19 (2020) 100290
Contents lists available at ScienceDirect
Obesity Medicine
journal homepage: www.elsevier.com/locate/obmed
Short communication
Metformin use is associated with reduced mortality rate from coronavirus
disease 2019 (COVID-19) infection
Timotius Ivan Hariyanto a, Andree Kurniawan b, *
a
b
Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Street, Karawaci, Tangerang, 15811, Indonesia
Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Street, Karawaci, Tangerang, 15811, Indonesia
A R T I C L E I N F O
A B S T R A C T
Keywords:
Coronavirus disease 2019
COVID-19
Metformin
Diabetes
Treatment
Background and aims: The coronavirus disease 2019 (COVID-19) pandemic has caused a significant impact on all
aspects of life. One of the comorbidities associated with severe outcome and mortality of COVID-19 is diabetes.
Metformin is one of the drugs which is most commonly used for the treatment of diabetes patients. This study
aims to analyze the potential benefit of metformin use in reducing the mortality rate from COVID-19 infection.
Methods: We systematically searched the Google Scholar database using specific keywords related to our aims
until August 3rd, 2020. All articles published on COVID-19 and metformin were retrieved. Statistical analysis
was done using Review Manager 5.4 software.
Results: A total of 5 studies with a total of 6937 patients were included in our analysis. Our meta-analysis showed
that metformin use is associated with reduction in mortality rate from COVID-19 infections [RR 0.54 (95% CI
0.32–0.90), p = 0.02, I2 = 54%, random-effect modelling].
Conclusion: Metformin has shown benefits in reducing the mortality rate from COVID-19 infections. Patients with
diabetes should be advised to continue taking metformin drugs despite COVID-19 infection status.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit